|
Originally published In Press as doi:10.1074/jbc.M107992200 on November 16, 2001
J. Biol. Chem., Vol. 277, Issue 3, 1991-1999, January 18, 2002
Coordinated Activation of Autophosphorylation Sites in the RET
Receptor Tyrosine Kinase
IMPORTANCE OF TYROSINE 1062 FOR GDNF MEDIATED NEURONAL
DIFFERENTIATION AND SURVIVAL*
Muriel
Coulpier ,
Jonas
Anders§, and
Carlos F.
Ibáñez¶
From the Division of Molecular Neurobiology, Department of
Neuroscience, Karolinska Institute, S-171 77 Stockholm, Sweden
Received for publication, August 20, 2001, and in revised form, October 31, 2001
 |
ABSTRACT |
The catalytic and signaling
activities of RET, a tyrosine kinase receptor for glial cell
line-derived neurotrophic factor (GDNF), are controlled by the
autophosphorylation of several tyrosine residues in the RET cytoplasmic
domain. To analyze the phosphorylation state of individual tyrosines,
we generated antibodies recognizing specific phosphotyrosine sites
involved in the catalytic (Tyr905) and downstream
signaling (Tyr1015, Tyr1062, and
Tyr1096) activities of this receptor. Stimulation with GDNF
induced coordinated phosphorylation of the 4 tyrosine residues in
neuronal cell lines and in primary cultures of sympathetic neurons
isolated from rat superior cervical ganglia. Neurturin and
artemin, two other members of the GDNF ligand family, also induced
synchronized phosphorylation of RET tyrosines with kinetics comparable
to those observed with GDNF. Tyrosine phosphorylation was maximal 15 min after ligand stimulation, decaying thereafter with similar kinetics
in all 4 residues. Co-stimulation with a soluble form of the GFR 1
co-receptor potentiated ligand-dependent phosphorylation of
different intracellular tyrosines to a similar extent and increased the
survival of superior cervical ganglion neurons compared with treatment
with GDNF alone. In vivo, high levels of phosphorylated
Tyr905, Tyr1015, and Tyr1062 were
detected in embryonic mouse dorsal root ganglia, with a sharp decline
at early postnatal stages. Protein transduction of
anti-Tyr(P)1062 antibodies into cultured cells
reduced activation of MAPKs ERK1 and ERK2 and the AKT
kinase in response to GDNF and diminished GDNF-dependent
neuronal differentiation and survival of embryonic sensory neurons from
the nodose ganglion. These results demonstrate synchronized utilization
of individual RET tyrosine residues in neurons in vivo and
reveal an important role for RET Tyr1062 in mediating
neuronal survival by GDNF.
 |
INTRODUCTION |
The GDNF1 ligand family,
a group of polypeptides structurally related to the transforming growth
factor- superfamily, is involved in the control of neuronal survival
and differentiation, kidney morphogenesis, and spermatogonial cell fate
(1-4). Each of the four members of the GDNF family (i.e.
GDNF, NTN, ART, and PSP) binds specifically to different members
of a small family of glycosylphosphatidylinositol-anchored receptors,
the GDNF family -receptors, of which four different members
(GFR 1-4) are currently known (1, 2, 5). Intracellular signaling is
accomplished by the recruitment of a receptor tyrosine kinase, RET, to
the GDNF·GFR complex. Although all members of the GDNF ligand
family utilize RET as a signaling receptor subunit, specificity is
achieved by differential binding to individual GFR molecules. GFR
receptors can mediate activation of RET when expressed on the surface
of the same cell (activation in cis) or when presented in
soluble form or immobilized on the cell matrix or neighboring cells
(activation in trans) (6, 7). Upon ligand binding, RET is
thought to form dimers and become phosphorylated at specific
cytoplasmic tyrosine residues. Tyrosine autophosphorylation is required
for the catalytic activity of RET and for downstream signaling. Thus,
tyrosine autophosphorylation constitutes the first intracellular event
of the RET signaling cascade activated by members of the GDNF ligand family.
Eighteen tyrosine residues, 2 in the juxtamembrane domain, 11 in the
kinase domain, and 5 in the carboxyl-terminal tail, are present in the
cytoplasmic domain of the long isoform of RET. Tyrosine 905 in the RET
kinase domain corresponds to tyrosine 416 in the activation loop of the
cytoplasmic tyrosine kinase Src, a conserved residue in many tyrosine
kinases known to play a crucial role in kinase activation (8). Mutation
of tyrosine 905 to phenylalanine (Y905F) impairs the kinase activity
and abolishes the transforming activity of RET-MEN2A, an oncogenic,
constitutively active form of RET identified in patients with multiple
endocrine neoplasia type 2A (9). Tyrosine 905 is also involved in the binding of two adaptor proteins containing SH2 domains, Grb7 and Grb10,
presumably involved in downstream signaling events (10-12). Six
additional tyrosines (Tyr687 in the juxtamembrane domain;
Tyr826 in the catalytic domain; and Tyr1015,
Tyr1029, Tyr1062, and Tyr1096 in
the carboxyl-terminal tail) have been shown to be autophosphorylated in
various oncogenic forms of RET by site-directed mutagenesis and
phosphopeptide mapping experiments (13). The functional importance of
the phosphorylation of Tyr687, Tyr826, and
Tyr1029 is unknown. On the other hand, phosphorylation of
Tyr1015, Tyr1062, and Tyr1096 has
been linked to distinct downstream signaling events. Tyrosine 1015 is
part of the motif YLXL, a docking site for phospholipase C ; and mutation of the corresponding residue in the
RET/PTC2 oncogene impairs its ability to activate
phospholipase C and reduces drastically its oncogenic activity in
NIH 3T3 cells (14). Tyrosine 1062 is part of the motif NKXY,
which constitutes a docking site for the phosphotyrosine-binding domain
of Shc and FRS2 adaptor proteins. Interaction between phosphorylated
Tyr1062 and either of these two adaptors leads to
activation of the Ras/ERK and PI3K/AKT pathways in oncogenic as well as
ligand-activated RET (15-20). Interestingly, the splicing event that
leads to the generation of the short and long isoforms of RET takes
place precisely after Tyr1062 and places this tyrosine
residue in a perfect context for binding to SH2 domains in the short
(but not the long) RET isoform. Thus, both phosphotyrosine-binding
domain-containing and SH2 domain-containing target proteins may bind to
this phosphorylated tyrosine in the short RET isoform. Tyrosine 1062 has also been implicated in the binding of Enigma to RET (12), although
this interaction appears to be independent of tyrosine phosphorylation.
Recently, a role for this tyrosine residue in the docking and
activation of different members of the Dok family of adaptor molecules
has also been demonstrated (21). Mutation of tyrosine 1062 (Y1062F)
dramatically impairs the transforming activity of oncogenic RET-MEN2A
and RET-MEN2B (22). Despite its high degree of connectivity to multiple
intracellular pathways, the biological function of this residue in the
wild-type RET receptor has not been investigated. Finally, tyrosine
1096, located in the 51-residue carboxyl-terminal tail that is specific for the long isoform of RET, is part of the sequence
PYXNX, a well known binding site for the Grb2
adaptor protein. Grb2 has been found to interact with the long isoform
of RET/PTC2 and wild-type RET via this residue (17, 23).
In this work, we have investigated the phosphorylation of individual
tyrosine residues in the cytoplasmic domain of RET in cell lines,
cultured primary neurons, and in vivo. We have studied differences in the kinetics of phosphorylation and dephosphorylation of
individual residues and whether different members of the GDNF ligand
family may be capable of inducing distinct patterns of tyrosine
phosphorylation in RET. For this purpose, we have generated antibodies
recognizing the specific phosphorylation of tyrosines 905, 1015, 1062, and 1096 in this receptor. We have introduced several of these
phosphotyrosine-specific antibodies into cell lines and primary neurons
to investigate the functional roles played by individual tyrosine
residues of RET in GDNF-mediated downstream signaling and neuronal survival.
 |
EXPERIMENTAL PROCEDURES |
Cell Lines and Reagents--
The MG87- 1/RET and
MG87- 3/RET lines were derived from MG87 fibroblasts by stable
transfection of GDNF receptor subunits. MG87- 1/RET cells express rat
GFR 1 and the long isoform of human RET. MG87- 3/RET cells express
mouse GFR 3 and the long isoform of human RET. Neuro2A- 1 cells
were generated by stable transfection of the mouse neuroblastoma
Neuro2A with rat GFR 1. MN1 is an immortalized mouse motor neuron
cell line (24). Recombinant rat GDNF was produced in Sf21 insect
cells and purified as previously described (25). Nerve growth factor
(NGF) was purchased from Promega, NTN from PeproTech, and GFR 1-Fc
from R&D Systems. Recombinant ART was a generously provided by Bob
Gordon (Jannssen Research Foundation, Beerse, Belgium). The
Chariot reagent used for protein transduction was from ActiveMotive
(Rixensart, Belgium).
Generation of Antibodies--
Phosphorylated 15-mer peptides
corresponding to four predicted phosphorylation sites in the long
isoform of the mouse RET receptor (see Table I) were synthesized,
coupled to keyhole limpet hemocyanin, and used to immunize rabbits by
standard procedures. Antisera were evaluated by enzyme-linked
immunosorbent assays against phosphorylated and
unphosphorylated versions of the peptides. Peptide synthesis,
rabbit immunizations, and antibody collection was done by Research
Genetics. Antisera showing high titer in enzyme-linked immunosorbent
assays were then screened by immunoblotting with protein extracts from
control and GDNF-stimulated MG87- 1/RET cells. Reactive antisera were
purified by sequential affinity chromatography steps. Total
immunoglobulins were first purified on a protein G column (POROS G,
PerSeptive Biosystems) and eluted with 0.1 M glycine (pH
2.7). Antisera to Tyr(P)905, Tyr(P)1015, and
Tyr(P)1062 showed little or no cross-reactivity against
unphosphorylated RET or irrelevant phosphotyrosines and were then
affinity-purified over an Affi-Gel 15 affinity column (Bio-Rad) coupled
with the corresponding phosphopeptides. Because the
anti-Tyr(P)1096 antisera demonstrated cross-reactivity with
unphosphorylated RET as well as other phosphotyrosines, these
antibodies were first applied to an Affi-Gel 15 affinity column coupled
with the unphosphorylated Tyr1096 peptide, followed by
chromatography on a phosphotyrosine affinity column (Sigma). The eluent
from these two steps was then applied to an Affi-Gel affinity column
coupled with the Tyr(P)1096 phosphopeptide.
Affinity-purified antibodies were eluted with 0.1 M glycine
(pH 2.7), immediately neutralized with 1 M Tris-HCl (pH
9.0), and dialyzed against Tris-buffered saline.
Immunoprecipitation and Immunoblot Analysis--
Cell line
monolayers in 10-cm plates were changed to serum-free medium 2-4 h
prior to stimulation with the indicated factors (10 min unless
otherwise indicated). Cells were then lysed in a nonionic ice-cold
detergent (lysis buffer: 10 mM Tris-HCl (pH 7.5), 137 mM NaCl, 2 mM EDTA, 10% glycerol, and 1%
Nonidet P-40) containing a mixture of protease inhibitors (Roche
Molecular Biochemicals) and phosphatase inhibitors (1 mM
NaO4Va. 20 mM NaF, and 10 mM -glycerophosphate). Cell lysates were cleared by centrifugation at
1500 × g for 10 min and immunoprecipitated by
overnight incubation at 4 °C with anti-RET antibodies and 40 µl of
protein G-Sepharose beads (Amersham Biosciences, Inc.). The
immunoprecipitates were washed three times with lysis buffer,
solubilized in sample buffer, run on SDS-polyacrylamide gels, and
blotted onto polyvinylidene difluoride membranes (Amersham Biosciences,
Inc.). Blots were first probed with anti-phosphopeptide antibodies,
followed by alkaline phosphatase-conjugated anti-IgG, and developed
with the enhanced chemi fluorescence Western detection system
(Amersham Biosciences, Inc.). All blots were scanned in a Storm 840 fluorimager (Molecular Dynamics, Inc.). For reprobing, blots
were stripped for 90 min at room temperature in 0.1 M
acetic acid and 0.15 M NaCl. Antibodies against
phosphotyrosine (used at 1:1000 dilution) and the long (1:1000) and
short (1:500) isoforms of human RET were from Santa Cruz Biotechnology.
For peptide competition assays, phosphorylated and unphosphorylated
peptides at 10 or 100 nM were preincubated with the
antibodies for 30 min at room temperature, and the mixture was then
used in immunoblotting.
For developmental analysis of RET phosphorylation, DRG were collected
from C57 mice at embryonic day (E) 15, E17, postnatal day (P) 0, P9,
P16, and the adult stage in ice-cold Tris-buffered saline containing 1 mM NaO4Va. DRG from three mice were pooled for
each embryonic time point, whereas DRG from one mouse were enough for
postnatal stages. Tissues were lysed in 70 µl of 1% lysis buffer,
cleared by centrifugation, submitted to SDS-PAGE, and immunoblotted
onto polyvinylidene difluoride membranes as described above. Each blot
was first probed with an anti-phosphopeptide antibody, stripped, and
then reprobed with anti-RET antibodies.
SCG, DRG, and Nodose Ganglion Primary Neuronal Cultures and
Survival Assays--
P1 rat SCG were dissociated by incubation for 30 min at 37 °C in phosphate-buffered saline containing 0.025% trypsin
(Invitrogen) and for an additional 30 min after addition of 5 mg/ml collagenase (Sigma), followed by mechanical trituration.
Dissociated cultures from E17 mouse DRG and E9 chick nodose ganglia
were prepared by incubation for 10 min at 37 °C in
phosphate-buffered saline containing 0.025% trypsin, without
collagenase and NGF treatments. Neurons were plated in
polyornithine/laminin-coated dishes and maintained in neuronal medium
(1:1 Dulbecco's modified Eagle's medium/nutrient mixture F-12,
Invitrogen), 2 mM glutamine, and 1 mg/ml bovine serum
albumin. SCG and nodose ganglion cultures were supplemented with 10 µM cytosine -D-arabinofuranoside. SCG
neurons were maintained in 20 ng/ml NGF. For biochemical analyses,
neurons were maintained for 4 days before a 4-h starvation
(i.e. without NGF in the case of SCG) and stimulation with
GDNF (100 ng/ml) in the presence or absence of soluble GFR 1-Fc (100 ng/ml) for the indicated times. The cells were then lysed, and lysates
were processed by SDS-PAGE and immunoblotting as described above.
For survival assays, SCG neurons were first maintained for 2 days in
neuronal medium supplemented with NGF; washed; and changed to neuronal
medium containing either NGF (100 ng/ml) or anti-NGF antibodies (Roche
Molecular Biochemicals) together with GDNF (100 ng/ml) and, where
indicated, soluble GFR 1-Fc (100 ng/ml). DRG neurons were plated
directly with the indicated factors without NGF preincubation.
Phase-bright, neurite-bearing neurons were counted 24 and 48 h
after treatment.
Chariot-mediated Protein Transduction--
MN1 cells and chick
nodose ganglion neurons were cultured in 24-well plates. Protein
transduction using the Chariot reagent was essentially performed
according to the manufacturer's instructions. In our hands, the
highest efficiency of protein transduction was obtained if performed in
serum-free medium with cells still in suspension prior to plating.
Because SCG neurons need to be treated for a few days with NGF to
develop GDNF responsiveness, antibody transduction was performed in
embryonic chick nodose ganglion neurons, which are readily responsive
to GDNF immediately after extraction (25). Two µg of antibody was
used together with 2 µl of Chariot reagent.
After Chariot-mediated transduction, MN1 cells were first allowed to
adhere to the plastic plate for 4 h and then stimulated for 5 min
with 100 ng/ml GDNF. The cells were lysed as described above, and 10 µg of protein lysate was processed by SDS-PAGE and immunoblotting
with antibodies against phosphorylated ERK1/2 or phosphorylated
AKT (Cell Signaling, New England Biolabs Inc.) at 1:2000
dilution. As a control for loading, the blot was stripped and reprobed
with total anti-AKT antibodies (Cell Signaling, New England Biolabs
Inc.) used at 1:1000 dilution or anti-tubulin antibodies. Neurite
outgrowth assay of MN1 cells was performed as previously described (7).
For survival assay, neurons were plated after Chariot-mediated
transduction and maintained in 100 ng/ml GDNF for 48 h.
Phase-bright neurons were counted in the entire well (between 100 and
400 neurons/well); the results presented are averages of three
different wells.
 |
RESULTS |
Generation and Characterization of Antibodies to
Individual Phosphotyrosine Sites in RET--
To produce polyclonal
antibodies directed against specific phosphotyrosine sites in RET, we
immunized rabbits with 15-mer synthetic phosphopeptides
corresponding to four distinct motifs in the cytoplasmic domain
of mouse RET. The phosphotyrosine motifs targeted by this approach
included Tyr(P)905, Tyr(P)1015,
Tyr(P)1062, and Tyr(P)1096. These sequence
motifs are highly conserved in RET from other vertebrate species,
including rat, chicken, and human (Table
I). The antibodies were purified from
rabbit sera by sequential affinity chromatography steps as described
under "Experimental Procedures."
View this table:
[in this window]
[in a new window]
|
Table I
Sequences of peptides used for immunization (based on mouse RET)
aligned in the corresponding regions of rat, chicken, and human RET
Dots indicate identical positions in the alignment. Phosphorylated
tyrosine residues are shown in boldface. Known downstream targets are
indicated. PLC , phospholipase C .
|
|
In fibroblast cells stably expressing the GFR 1 co-receptor and the
long isoform of human RET (MG87- 1/RET), antibodies against Tyr(P)905, Tyr(P)1015, Tyr(P)1062,
and Tyr(P)1096 specifically recognized phosphorylated RET
in cells treated with GDNF, but not in untreated cells (Fig.
1A). Similar results were obtained in a mouse motor neuron cell line (MN1) endogenously expressing GDNF receptors (data not shown). Competition experiments indicated that each of the antibodies was specific for the
phosphorylated form of its cognate peptide, as only the corresponding
phosphopeptide (but not the unphosphorylated peptide or other unrelated
phosphopeptides) was able to block the detection of activated RET (Fig.
1A). The specificity of the antibodies was further tested in
fibroblast cells stably expressing mutant forms of human RET carrying
specific amino acid replacements of cytoplasmic tyrosines, namely
Y1015F, Y1062F, and Y1096F. In each case, detection of ligand-activated RET was abolished by mutation of the corresponding tyrosine residue to
phenylalanine (Fig. 1B), whereas replacement of non-cognate tyrosines had no effect (data not shown). Because mutation of Tyr905 affects the kinase activity of the receptor, the
specificity of the antibodies against Tyr(P)905 was tested
in COS cells transiently overexpressing RET carrying the Y905F
mutation. Overexpression in COS cells led to high levels of
ligand-independent RET phosphorylation, even in the Y905F mutant, which
could be detected with anti-phosphotyrosine antibodies (data not shown)
or anti-Tyr(P)1015 antibodies (Fig. 1B), but not
with antibodies against Tyr(P)905 (Fig. 1B).
Because the peptides used for immunization contain sequence motifs that
partially overlap with analogous sites in other tyrosine kinase
receptors, we tested the ability of our antibodies to detect tyrosine
phosphorylation in the neurotrophin-4 receptor TrkB, which, like RET,
also contains phosphotyrosine docking sites for Shc, FRS2, and
phospholipase C . However, none of the four antibodies was able to
recognize ligand-activated TrkB (Fig. 1C), indicating that
they are indeed specific for the phosphorylation status of distinct
tyrosine residues in RET.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Characterization of antibody
specificity. A, competition with unphosphorylated or
irrelevant phosphorylated peptides. Shown are immunoblots of RET
immunoprecipitates from lysates of MG87- 1/RET cells stimulated with
GDNF. Blots were probed with the indicated anti-phosphopeptide
antibodies after preincubation with the indicated peptides and
phosphopeptides (used at 100 nM) (upper panels).
The blots were then reprobed with anti-RET antibodies (lower
panels). B, immunoreactivity tested against RET
molecules carrying specific tyrosine mutations. Shown are immunoblots
of RET immunoprecipitates from lysates of cells transfected with
wild-type (wt) or the indicated mutant human RET receptors
(upper panels). Transiently transfected COS cells were used
for the first panel group probed with
anti-Tyr(P)905 antibodies. The other three panel
groups show MG87- 1/RET cells (wt) or MG87- 1 cells
stably transfected with the indicated RET mutants after stimulation
with GDNF as indicated. The blots were reprobed with anti-RET
(lower panels) and anti-Tyr(P) (middle panels)
antibodies. C, lack of reactivity against phosphotyrosine
(PY) epitopes in another receptor tyrosine kinase. Shown are
immunoblots of TrkB immunoprecipitates from lysates of MG87-TrkB cells
stimulated with neurotrophin-4 (NT-4) and probed with the
indicated anti-phosphopeptide antibodies (upper panels). The
blots were reprobed with total anti-phosphotyrosine (P-Tyr)
antibodies (lower panels).
|
|
Synchronized Phosphorylation of Individual Tyrosine Residues
following Activation of RET in Cis--
To study the kinetics of
phosphorylation of individual tyrosine residues in RET after ligand
stimulation, we used fibroblast cell lines expressing GFR 1 or
GFR 3 together with the wild-type RET receptor (MG87- 1/RET and
MG87- 3/RET, respectively) and MN1 cells expressing endogenous
GFR 1, GFR 2, and RET receptors. GDNF stimulation elicited
synchronized phosphorylation of tyrosines 905, 1015, 1062, and 1096 in
MG87- 1/RET cells, corresponding to the pattern of total tyrosine
phosphorylation detected by phosphotyrosine antibodies (Fig.
2A). RET phosphorylation was
maximal between 10 and 15 min after ligand stimulation and could still
be detected after 120 min (Fig. 2A). Dephosphorylation of
the 4 tyrosines following maximal activation also proceeded with
comparable kinetics in all cases (Fig. 2A). Similar results
were obtained in MN1 cells, except that tyrosine phosphorylation
decayed more rapidly in these cells compared with fibroblast cells
(Fig. 2B). Differences in the kinetics of receptor
phosphorylation in different cell types could be due to different
levels of receptor expression, as shown for the NGF receptor TrkA (26),
or to different complements of protein-tyrosine phosphatases.
Phosphorylation of Tyr905, Tyr1015, and
Tyr1062 was also detected in the short isoform of RET after
immunoprecipitation from MN1 cells (data not shown). No differences
could be seen between the two RET isoforms regarding activation of
individual phosphotyrosine residues.

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 2.
Synchronized phosphorylation of individual
tyrosine residues following activation of RET in cis. Shown
are representative immunoblots of RET immunoprecipitates from lysates
of MG87- 1/RET cells (A and C), MN1 cells (B
and D), and MG87- 3/RET cells (E) after
stimulation with the indicated ligands (GDNF (A and
B), NTN (C and D), and ART
(E)) for the indicated periods of time (in minutes).
Indicated to the left are the antibodies used for immunoblotting in
each case. Although small differences could be seen between individual
tyrosine sites within a given experiment, these were not consistent
from experiment to experiment, indicating that phosphorylation and
dephosphorylation were coordinated in the four sites studied.
PY and P-Tyr, phosphotyrosine.
|
|
We also investigated whether different ligands of the GDNF family could
induce distinct patterns of phosphorylation of individual tyrosine
residues in RET. Stimulation of MG87- 1/RET fibroblasts or MN1 cells
with NTN resulted in a phosphorylation pattern very similar to that
observed with GDNF (Fig. 2, C and D). Also ART, signaling via GFR 3 in MG87- 3/RET cells, induced a pattern of tyrosine phosphorylation comparable to those of GDNF and NTN (Fig. 2E). Thus, we conclude that Tyr905,
Tyr1015, Tyr1062, and Tyr1096
become phosphorylated and dephosphorylated in a synchronized manner
after ligand stimulation and that different GDNF family ligands
utilizing different GFR receptors induce comparable patterns of
tyrosine phosphorylation.
Synchronized Phosphorylation of Individual Tyrosine Residues
following Activation of RET in Trans and Increased Phosphorylation upon
Combined in Cis/Trans Activation--
The effects of GDNF stimulation
of RET in cis (i.e. GFR 1 expressed in the same
cell) versus in trans (i.e. GFR 1
supplied exogenously) on the pattern of phosphorylation of individual
tyrosines was examined in Neuro2A cells, a mouse neuroblastoma
expressing endogenous RET, but little or no GFR 1. Treatment with
GDNF alone produced no detectable RET phosphorylation in parental
Neuro2A cells (data not shown). In Neuro2A cells stably transfected
with GFR 1 (Neuro2A- 1), GDNF induced rapid and transient RET
phosphorylation, which returned to basal levels 60 min after
treatment (Fig. 3A). In
contrast, stimulation of parental Neuro2A cells with GDNF and a soluble
form of GFR 1 (GFR 1-Fc) resulted in a delayed but sustained phosphorylation of RET, which persisted for up to 120 min after treatment (Fig. 3B). Similar to the results observed after
stimulation in cis, phosphorylation of Tyr905,
Tyr1015, and Tyr1062 was synchronized following
stimulation of Neuro2A cells with GDNF plus soluble GFR 1 (Fig.
3B). In agreement with the pattern of total RET tyrosine
phosphorylation, phosphorylation of individual tyrosines was delayed
until ~10 min and was sustained for up to 120 min (Fig.
3B). Finally, we compared the patterns of RET tyrosine phosphorylation in MN1 cells expressing RET and GFR 1 treated with
GDNF alone (in cis) versus GDNF plus soluble
GFR 1 (in cis + in trans), a situation more
likely to be encountered by neurons that express RET and GFR 1
in vivo. In this case, treatment with soluble GFR 1 both
potentiated and prolonged phosphorylation of individual RET tyrosines
compared with GDNF alone (Fig. 3C). The phosphorylation
patterns of the individual residues were comparable, in support of a
synchronized mode of activation after stimulation in trans.
Phosphorylation of Tyr1096, present in the long RET isoform
only, could not be detected in Neuro2A or MN1 cells (data not shown).
We think this is due in part to the relatively lower sensitivity of
this antibody and also to the fact that, in contrast to the MG87 cell
lines used above stably transfected with the RET long isoform, both
Neuro2A and MN1 cells express endogenous levels of the short and long isoforms of RET, of which only the latter can be recognized by the
anti-Tyr(P)1096 antibody.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 3.
Synchronized phosphorylation of individual
tyrosine residues following activation of RET in trans
and increased phosphorylation upon combined in
cis/trans activation. A, RET
phosphorylation in cis. Shown is an immunoblot of RET
immunoprecipitates from lysates of Neuro2A- 1 cells stimulated with
GDNF for different times (in minutes) and probed with total
anti-phosphotyrosine (P-Tyr) antibodies. B, RET
phosphorylation in trans. Shown are immunoblots of RET
immunoprecipitates from lysates of parental Neuro2A cells stimulated
with GDNF and soluble GFR 1-Fc for different times (in minutes).
Indicated to the left are the antibodies used for immunoblotting in
each case. The lower panel shows the final reprobing with
anti-RET antibodies. C, combined in cis/trans RET
stimulation. Shown are immunoblots of RET immunoprecipitates from
lysates of MN1 cells stimulated with GDNF (in cis) or a
combination of GDNF and soluble GFR 1-Fc (in cis + in
trans) for different times (in minutes). Indicated to the
left are the antibodies used for immunoblotting in each case. The
lower panel shows the final reprobing with anti-RET
antibodies. PY, phosphotyrosine.
|
|
Phosphorylation of RET Tyrosines 905, 1015, and 1062 in Neurons in
Vitro and in Vivo--
We then used our antibodies to investigate the
phosphorylation of individual RET tyrosine residues in neurons
stimulated with GDNF in vitro. GDNF treatment of primary
cultures of P1 rat SCG neurons or E9 chick nodose ganglion neurons
induced robust phosphorylation of Tyr905,
Tyr1015, and Tyr1062 (Fig.
4A). Phosphorylation of
Tyr1096 could not be detected in primary neuronal cultures,
probably due to the lower sensitivity of this antibody (see above). The individual tyrosines at positions 905 and 1015 also appeared to be
phosphorylated in a coordinated way in primary neurons, as was observed
in cell lines (Fig. 4B), with a peak at 10 min and lower
levels at 120 min after GDNF stimulation. Similar to MN1 cells,
addition of soluble GFR 1 potentiated and prolonged the phosphorylation of these sites, allowing its detection for up to
24 h of treatment (Fig. 4B). The increased
phosphorylation observed in the presence of soluble GFR 1 correlated
with enhanced survival in culture compared with GDNF alone (Fig.
4C).

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 4.
Phosphorylation of RET tyrosines 905, 1015, and 1062 in neurons in vitro and in vivo.
A, phosphorylation of individual RET tyrosines in cultures
of P1 rat SCG neurons and E9 chick nodose neurons. The blots show
direct probing with the indicated antibodies of lysates from cells
treated with GDNF for 10 min as indicated. The lower panels
show the final reprobing with anti-RET antibodies. B,
kinetics of tyrosine phosphorylation in rat SCG neurons in
cis and in trans. The blots show direct probing
with the indicated antibodies of lysates from cells treated with GDNF
or GDNF plus GFR 1-Fc (both at 100 ng/ml) for the indicated periods
of time (in minutes). The lower panel shows the final
reprobing with anti-RET antibodies. C, survival of P1 rat
SCG neurons with GDNF in the presence and absence of soluble GFR 1-Fc
scored 24 and 48 h after treatment. Anti-NGF blocking antibodies
were included as indicated. Results are expressed relative to the
survival observed in NGF (set to 100%) and represent the means ± S.E. of three independent experiments performed in triplicate.
D, phosphorylation of individual RET tyrosine residues
in vivo in mouse DRG. Shown are immunoblots of equal amounts
of protein from lysates of mouse DRG extracted at the indicated
developmental stages and probed with the indicated phosphopeptide
antibodies. The blots were reprobed with anti-RET antibodies
(lower panels). E, survival of E17 mouse DRG
neurons with GDNF in the presence and absence of soluble GFR 1-Fc
scored 48 h after treatment. Results are expressed relative to the
survival observed in NGF (set to 100%) and represent the means ± S.E. of three independent experiments performed in duplicate.
PY, phosphotyrosine; AD, adult.
|
|
The phosphorylation patterns of individual tyrosine residues in RET
were investigated in mouse DRG developing in vivo. Although DRG sensory neurons express both RET and GFR receptors during embryonic development, they have been found to respond in
vitro to GDNF only at postnatal stages (27). We found robust
phosphorylation of Tyr905, Tyr1015, and
Tyr1062 in DRG taken from E15 and E17 mouse embryos (Fig.
4D). Interestingly, phosphorylation of the 3 residues
declined sharply shortly after birth to levels that were barely above
detection at postnatal and adult stages (Fig. 4D). In
agreement with a role for RET and GFR receptors in neuronal survival
of embryonic mouse DRG neurons, GDNF promoted survival in
vitro of dissociated E17 mouse DRG neurons (Fig. 4E).
As in SCG neurons, addition of soluble GFR 1-Fc potentiated the
survival response of embryonic DRG neurons to GDNF (Fig.
4E).
Phosphorylation of Tyr1062 Is Required for RET
Downstream Signaling and GDNF-mediated Survival of Sensory
Neurons--
Mutations of RET Tyr1062 affect the ability
of GDNF to induce activation of the Ras/ERK and PI3K/AKT pathways in
transfected fibroblast cells (17). The ability of our
anti-phosphopeptide antibodies to specifically recognize individual
phosphorylated tyrosines in RET prompted us to test the importance of
these residues for neuronal survival induced by GDNF. Purified
antibodies were introduced into cells in culture using Chariot-mediated
protein transduction (see "Experimental Procedures"). Control
experiments using tetramethylrhodamine B isothiocyanate-labeled
control antibodies demonstrated that nearly 100% of the MN1 cells took
up the antibodies only in the presence of the Chariot reagent and
without any appreciable toxic effects (data not shown). In MN1 cells,
transduction of anti-Tyr(P)1062 antibodies reduced
activation of ERK1 and ERK2 in response to GDNF (Fig.
5A). No inhibitory effect on
ERK phosphorylation could be seen when the Chariot reagent or
antibodies were used separately (Fig. 5A). Because
Tyr1062 is also linked with the PI3K pathway and activation
of the AKT kinase (17), we tested phosphorylation of AKT in MN1 cells
after transduction with anti-Tyr(P)1062 antibodies. In the
presence of the Chariot reagent, anti-Tyr(P)1062 antibodies
diminished AKT phosphorylation in MN1 cells treated with GDNF (Fig.
5A), demonstrating that treatment with
anti-Tyr(P)1062 antibodies likely affects all downstream
signaling mediated by Tyr1062 in RET.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 5.
Phosphorylation of Tyr1062 is
required for RET downstream signaling and GDNF-mediated survival of
sensory neurons. A, analysis of ERK and AKT
phosphorylation in MN1 cells. The upper panels shows
phosphorylated ERK (P-ERK) and phosphorylated AKT
(P-AKT) immunoblots of MN1 cell lysates treated with GDNF
and Chariot-antibody conjugates as indicated. The blots were reprobed
with total anti-AKT antibodies (lower left panel) or
anti-tubulin antibodies (lower right panel). B,
neurite outgrowth induced by GDNF and GFR 1 in MN1 cells treated with
different Chariot-antibody conjugate combinations. Cells with neurites
longer than two-cell diameters were counted in different fields of
independent wells. Results are expressed as -fold increase over control
(set to 1) and represent the means ± S.E. of three independent
experiments performed in triplicate. *, p < 0.05 versus GDNF + GFR 1. C, GDNF-mediated survival
of E9 chick nodose ganglion neurons treated with different
Chariot-antibody conjugate combinations. Guinea pig anti-goat Ig
antibodies were used as a control. Results are expressed relative to
the survival observed in GDNF alone (set to 100%) and represent the
means ± S.E. of three independent experiments performed in
triplicate. *, p < 0.05 versus GDNF.
PY, phosphotyrosine.
|
|
To evaluate the role of individual RET phosphotyrosine residues in
GDNF-mediated biological activities, we used a neurite outgrowth assay
in MN1 cells and a survival assay in sensory neurons isolated from the
developing chick nodose ganglion, a neuronal subpopulation that is
highly responsive to the survival-promoting effects of GDNF (25) (see
also "Experimental Procedures"). Cotreatment with GDNF and soluble
GFR 1 produces a robust morphological differentiation of MN1 cells
plated in a collagen matrix (7). Cells that were transduced with
anti-Tyr(P)1062 antibodies showed a greatly attenuated
response to the differentiation effects of GDNF + GFR 1 (Fig.
5B). Under the same conditions, neither
anti-Tyr(P)905 nor anti-Tyr(P)1015 antibodies
had any effect on MN1 neurite outgrowth (Fig. 5B). As
indicated above, all of our anti-phosphopeptide antibodies were capable
of recognizing activated RET in chick sensory neurons (Fig.
4A), in agreement with the high conservation of the
corresponding peptide sequences across different vertebrate species
(Table I). GDNF promoted a robust survival response in E9 nodose
ganglion neurons after 48 h in culture compared with controls
(Fig. 5C). Importantly, treatment with the Chariot reagent
alone or with an irrelevant antibody had no effect on GDNF-mediated
survival of sensory neurons (Fig. 5C). In the presence of
GDNF, transduction of anti-Tyr(P)1062 antibodies reduced
neuronal survival to 50% at 48 h compared with GDNF alone (Fig.
5C). Without the Chariot reagent,
anti-Tyr(P)1062 antibodies had no effect on GDNF-mediated
neuronal survival (Fig. 5C). Interestingly, neither
anti-Tyr(P)905 nor anti-Tyr(P)1015 antibodies
affected neuronal survival in the presence of GDNF (Fig.
5C), indicating a specific role of RET Tyr1062
phosphorylation in GDNF-mediated survival of sensory neurons.
 |
DISCUSSION |
Upon ligand stimulation, the RET tyrosine kinase receptor is
autophosphorylated at a set of cytoplasmic tyrosine residues. This autophosphorylation allows the binding and activation of signaling
molecules and therefore constitutes the first event of the
intracellular signaling pathway of this receptor. To study the
phosphorylation upon ligand stimulation of distinct tyrosine residues
in RET, we have developed antibodies to 4 individual phosphotyrosines
in this receptor: Tyr905 in the catalytic domain and
Tyr1015, Tyr1062, and Tyr1096 in
the carboxyl-terminal tail. Using a similar strategy, Salvatore et al. (28) have recently reported that tyrosines
1015 and 1062 are indeed autophosphorylated in oncogenic forms of RET
and that phosphorylation of Tyr1062 is required for the
mitogenic activities of the RET/PTC1 oncogene in a
carcinoma cell line. In this work, we have used antibodies against
Tyr(P)905, Tyr(P)1015, Tyr(P)1062,
and Tyr(P)1096 to demonstrate that these tyrosine residues
are phosphorylated upon ligand stimulation in cell lines and in primary
neurons expressing endogenous receptors in a synchronized way.
Coordinated autophosphorylation of individual tyrosines was observed
with different members of the GDNF ligand family using different GFR
receptors acting in cis or in trans. Our results
indicate that phosphorylation of individual tyrosines in RET is
developmentally regulated in the DRG in vivo. Finally, using
protein transduction into primary neuronal cultures, we demonstrated
that phosphorylation of Tyr1062 is directly involved in
GDNF-dependent neuronal survival.
Synchronized Phosphorylation of Individual RET Tyrosine Residues
upon Ligand-mediated Activation--
Based on crystallographic studies
on the insulin -receptor, Hubbard et al. (29) proposed
that autophosphorylation of a specific tyrosine(s) in the activation
loop is the initial event leading to receptor tyrosine kinase
activation. In this model, autophosphorylation of tyrosine 1162 of the
insulin -receptor is proposed to induce a conformational change that
exposes the ATP- and substrate-binding sites for catalysis.
Furthermore, phosphorylation of this site was found to be completed
before phosphorylation of other tyrosines began (30), suggesting a
stepwise mode of phosphorylation of tyrosine residues during kinase
activation. Moreover, in the TrkA receptor, the Shc binding at
Tyr490 remained phosphorylated for a longer time than at
tyrosines 674 and 675 in the activation loop (31). In contrast, our
results indicate that, in the RET receptor, tyrosines located within
the catalytic and signaling domains are phosphorylated and
dephosphorylated in a coordinated way, suggesting that stepwise
phosphorylation of activation loop tyrosines is not a general feature
of the mechanism of receptor tyrosine kinase activation.
The somewhat unexpected discovery that all four members of the GDNF
family signal through a common receptor tyrosine kinase raised the
possibility that the different ligands could activate RET in different
ways, perhaps through differential phosphorylation of cytoplasmic
tyrosines or via differences in strength and duration of
autophosphorylation events (32). In fact, several receptor tyrosine
kinases appear to be capable of generating different responses to
distinct ligands of otherwise comparable affinity. For example, the
neurotrophin receptor TrkB binds both brain-derived neurotrophic factor
and neurotrophin-4, and both ligands stimulate activation of MAPKs in
cortical neurons (33). However, only activation by neurotrophin-4
requires an intact Shc-binding site in the cytoplasmic domain of TrkB
(33), indicating differences in the signaling mechanisms activated by
these two neurotrophins via the TrkB receptor. It has also been shown
that the epidermal growth factor receptor can be activated with
different kinetics by its two ligands, epidermal growth factor and
transforming growth factor- (34) and, more recently, that the four
ligands of the ErbB4 receptor (betacellulin and neuregulins 1-3) are
able to elicit different patterns of tyrosine phosphorylation in this receptor (35). Although the limited biochemical evidence available suggests that GDNF and NTN may induce the activation of similar downstream pathways (36), more recent studies indicate that the two
ligands may have different biological effects. For example, both GDNF
and NTN are able to promote survival of midbrain dopaminergic neurons
after a 6-hydroxydopamine lesion, although only GDNF is capable
of stimulating neurite outgrowth from these neurons (37). In this
study, we investigated the phosphorylation patterns of individual
tyrosine residues in RET after stimulation with different ligands
(e.g. GDNF, NTN, and ART) and in cells expressing a single type of GFR co-receptor (e.g. MG87- 1/RET and
MG87- 3/RET cells) or combinations of different GFR receptors
(e.g. MN1 cells and peripheral neurons). In none of these
cases could we detect significant differences between the kinetics of
phosphorylation and dephosphorylation of different tyrosine residues in
RET. These observations indicate a robust mechanism of activation for
the RET kinase and suggest that the RET receptor is unable to
discriminate among different ligands or GFR co-receptors.
Differences in the biological activities elicited by different members
of the GDNF family could still be explained by the existence of
alternative, RET-independent signaling mechanisms, for which some
evidence has recently begun to accumulate (38, 39).
Increased and Prolonged Phosphorylation of Individual Tyrosine
Residues after Activation of RET in Cis plus in Trans--
Comparison
of tyrosine phosphorylation patterns in Neuro2A, Neuro2A- 1, and MN1
cells and SCG neurons after stimulation of RET in cis, in
trans, or in cis + in trans revealed
indistinguishable kinetics in the different phosphorylation sites
investigated under the three stimulation regimes, indicating no
preferential activation of specific tyrosine sites after stimulation
with soluble GFR 1 receptors. However, RET tyrosine phosphorylation
was increased and prolonged in cells stimulated in trans
with GDNF and soluble GFR 1 compared with GDNF alone. In addition, in
cells lacking GFR 1 receptors, RET tyrosine phosphorylation was
delayed after stimulation in trans compared with cells
expressing endogenous GFR 1 stimulated in cis
(i.e. Fig. 3, A and B). Thus, although RET is not able to discriminate among different ligands, a quantitative difference in the response of this receptor can be observed when the in
cis and in trans stimulation regimes are directly
compared. Potentiated and sustained RET tyrosine phosphorylation in SCG neurons after stimulation with GDNF and soluble GFR 1 correlated with
enhanced neuronal survival, comparable to the effects of NGF. Together
with recent observations made in developing enteric and sensory neurons
(7, 40), these results demonstrate the generalized potential of
exogenous GFR receptors to potentiate the trophic activities of GDNF
family ligands.
Robust Phosphorylation of Individual RET Tyrosine Residues during
Embryonic Development of DRG Neurons in Vivo--
As a first step
toward elucidating patterns of RET activation in vivo, we
investigated RET phosphorylation in freshly isolated mouse DRG from
embryonic and postnatal stages. Our results showed robust
phosphorylation of Tyr905, Tyr1015, and
Tyr1062 at embryonic stages (i.e. E15-17), with
a pronounced decrease at early postnatal stages, suggesting that DRG
neurons are exposed to high levels of GDNF family ligands during
embryonic development. In agreement with this, ART expression has been
detected in peripheral nerve roots at this developmental stage (41).
This observation indicates a role for GDNF ligands in the control of
neuronal survival and maturation and axonal growth of developing
sensory neurons. Intriguingly, a recent developmental study indicated
that cultures of dissociated mouse DRG neurons do not respond to the
survival-promoting effects of GDNF family ligands until after birth
(27). However, GDNF-null mutant mice display a 23% loss of DRG neurons
already at birth (42), indicating the requirement of this factor for the survival of DRG neurons during (at least some) embryonic stages in vivo. In agreement with this, we found that GDNF can
promote the survival of E17 mouse DRG neurons in vitro and
that this activity can be further potentiated by soluble GFR 1-Fc.
Finally, the fact that RET phosphorylation could be seen up to adult
stages (only Tyr(P)905 was analyzed here) indicates that
cells in the mouse DRG are continuously exposed to GDNF family ligands
in vivo. The functions of these factors in adult sensory
neurons are only beginning to be understood and may involve acute
regulation of physiological properties such as injury-induced
plasticity of sodium channel subunits (43).
Role of Tyr1062 in GDNF-mediated Neuronal
Differentiation and Survival--
Our results using protein
transduction of anti-phosphopeptide antibodies demonstrate for the
first time a role for RET Tyr1062 in GDNF-mediated neuronal
differentiation and survival. The high degree of connectivity of this
residue with a number of major intracellular pathways, including the
Ras/ERK and PI3K/AKT pathways, predicted an important role for
Tyr1062 in the biological activities of the RET receptor.
The fact that this residue constitutes a major (although not the only)
route by which RET activates PI3K and AKT, a crucial pathway for
GDNF-mediated survival of SCG neurons (17), is in agreement with its
importance for the biological activity of this receptor in sensory
neurons. On the other hand, the inability of anti-Tyr(P)905
and anti-Tyr(P)1015 antibodies to affect neuronal survival
suggests that none of their targets are involved in this activity.
Notably, the lack of effect of antibodies against
Tyr(P)905, a residue involved in the activation of the RET
kinase, indicates that, once phosphorylated, this tyrosine does not
participate in downstream events required for neuronal survival.
 |
ACKNOWLEDGEMENTS |
We thank Susanna Eketjäll for the
MG87- 3/RET cell line; Rizaldy Scott and Valerie Besset for RET
mutants and cell lines; Bob Gordon, Stefan Massuré, and Miroslav
Cik for providing recombinant ART; Marie Pierre Junier for critical
reading of the manuscript; and Xiaoli Li for secretarial help.
 |
FOOTNOTES |
*
This work was supported in part by Grant 3474-B97-05XBC from
the Swedish Cancer Society, Grant QLRT-1999-00099 from the Fifth Framework Program of the European Commission, the Göran
Gustafssons Stiftelse, and the Karolinska Institute.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Supported in part by grants from the Swedish Medical Research
Council and the Swedish Cancer Society.
§
Supported in part by Grant An 338/1-1 from the Deutsche
Forschungsgemeinschaft (Bonn, Germany).
¶
To whom correspondence should be addressed: Div. of Molecular
Neurobiology, Dept. of Neuroscience, Karolinska Inst., Retzius väg 8 A2:2, S-171 77 Stockholm, Sweden. Tel.: 46-8-728-7660; Fax:
46-8-33-9548; E-mail: carlos.ibanez@neuro.ki.se.
Published, JBC Papers in Press, November 16, 2001, DOI 10.1074/jbc.M107992200
 |
ABBREVIATIONS |
The abbreviations used are:
GDNF, glial cell
line-derived neurotrophic factor;
NTN, neurturin;
ART, artemin;
GFR , GDNF family receptor- ;
ERK, extracellular signal-regulated kinase;
PI3K, phosphatidylinositol 3-kinase;
NGF, nerve
growth factor;
DRG, dorsal root ganglion/ganglia;
SCG, superior
cervical ganglion/ganglia;
E, embryonic day;
P, postnatal day;
MAPKs, mitogen-activated protein kinases.
 |
REFERENCES |
| 1.
|
Airaksinen, M. S.,
Titievsky, A.,
and Saarma, M.
(1999)
Mol. Cell. Neurosci.
13,
313-325
|
| 2.
|
Baloh, R. H.,
Enomoto, H.,
Johnson, E. M., Jr.,
and Milbrandt, J.
(2000)
Curr. Opin. Neurobiol.
10,
103-110
|
| 3.
|
Meng, X.,
Lindahl, M.,
Hyvonen, M. E.,
Parvinen, M.,
de Rooij, D. G.,
Hess, M. W.,
Raatikainen-Ahokas, A.,
Sainio, K.,
Rauvala, H.,
Lakso, M.,
Pichel, J. G.,
Westphal, H.,
Saarma, M.,
and Sariola, H.
(2000)
Science
287,
1489-1493
|
| 4.
|
Sariola, H.,
and Saarma, M.
(1999)
Int. J. Dev. Biol.
43,
413-418
|
| 5.
|
Ibáñez, C. F.
(1998)
Trends Neurosci.
21,
438-444
|
| 6.
|
Yu, T.,
Scully, S., Yu, Y. B.,
Fox, G. M.,
Jing, S. Q.,
and Zhou, R. P.
(1998)
J. Neurosci.
18,
4684-4696
|
| 7.
|
Paratcha, G.,
Ledda, F.,
Baars, L.,
Coulpier, M.,
Besset, V.,
Anders, J.,
Scott, R.,
and Ibáñez, C. F.
(2001)
Neuron
29,
171-184
|
| 8.
|
Hanks, S. K.,
Quinn, A. M.,
and Hunter, T.
(1988)
Science
241,
42-52
|
| 9.
|
Iwashita, T.,
Asai, N.,
Murakami, H.,
Matsuyama, M.,
and Takahashi, M.
(1996)
Oncogene
12,
481-487
|
| 10.
|
Pandey, A.,
Liu, X.,
Dixon, J. E.,
Difiore, P. P.,
and Dixit, V. M.
(1996)
J. Biol. Chem.
271,
10607-10610
|
| 11.
|
Pandey, A.,
Duan, H., Di, F. P.,
and Dixit, V. M.
(1995)
J. Biol. Chem.
270,
21461-21463
|
| 12.
|
Durick, K., Wu, R. Y.,
Gill, G. N.,
and Taylor, S. S.
(1996)
J. Biol. Chem.
271,
12691-12694
|
| 13.
|
Liu, X.,
Vega, Q. C.,
Decker, R. A.,
Pandey, A.,
Worby, C. A.,
and Dixon, J. E.
(1996)
J. Biol. Chem.
271,
5309-5312
|
| 14.
|
Borrello, M. G.,
Alberti, L.,
Arighi, E.,
Bongarzone, I.,
Battisini, C.,
Bardelli, A.,
Pasini, B.,
Piutti, C.,
Rizzetti, M. G.,
Mondellini, P.,
Radice, M. T.,
and Pierotti, M. A.
(1996)
Mol. Cell. Biol.
16,
2151-2163
|
| 15.
|
Asai, N.,
Murakami, H.,
Iwashita, T.,
and Takahashi, M.
(1996)
J. Biol. Chem.
271,
17644-17649
|
| 16.
|
Arighi, E.,
Alberti, L.,
Torriti, F.,
Ghizzoni, S.,
Rizzetti, M. G.,
Pelicci, G.,
Pasini, B.,
Bongarzone, I.,
Piutti, C.,
Pierotti, M. A.,
and Borrello, M. G.
(1997)
Oncogene
14,
773-782
|
| 17.
|
Besset, V.,
Scott, R. P.,
and Ibáñez, C. F.
(2000)
J. Biol. Chem.
275,
39159-39166
|
| 18.
|
Segouffin-Cariou, C.,
and Billaud, M.
(2000)
J. Biol. Chem.
275,
3568-3576
|
| 19.
|
Kurokawa, K.,
Iwashita, T.,
Murakami, H.,
Hayashi, H.,
Kawai, K.,
and Takahashi, M.
(2001)
Oncogene
20,
1929-1938
|
| 20.
|
Melillo, R. M.,
Santoro, M.,
Ong, S. H.,
Billaud, M.,
Fusco, A.,
Hadari, Y. R.,
Schlessinger, J.,
and Lax, I.
(2001)
Mol. Cell. Biol.
21,
4177-4187
|
| 21.
|
Grimm, J.,
Sachs, M.,
Britsch, S., Di,
Cesare, S.,
Schwarz-Romond, T.,
Alitalo, K.,
and Birchmeier, W.
(2001)
J. Cell Biol.
154,
345-354
|
| 22.
|
Asai, N.,
Iwashita, T.,
Matsuyama, M.,
and Takahashi, M.
(1995)
Mol. Cell. Biol.
15,
1613-1619
|
| 23.
|
Alberti, L.,
Borrello, M. G.,
Ghizzoni, S.,
Torriti, F.,
Rizzetti, M. G.,
and Pierotti, M.
(1998)
Oncogene
17,
1079-1087
|
| 24.
|
Trupp, M.,
Arenas, E.,
Fainzilber, M.,
Nilsson, A.-S.,
Sieber, B. A.,
Grigoriou, M.,
Kilkenny, C.,
Salazar-Grueso, E.,
Pachnis, V.,
Arumäe, U.,
Sariola, H.,
Saarma, M.,
and Ibáñez, C. F.
(1996)
Nature
381,
785-789
|
| 25.
|
Trupp, M.,
Rydén, M.,
Jörnvall, H.,
Timmusk, T.,
Funakoshi, H.,
Arenas, E.,
and Ibáñez, C. F.
(1995)
J. Cell Biol.
130,
137-148
|
| 26.
|
Hempstead, B. L.,
Rabin, S. J.,
Kaplan, L.,
Reid, S.,
Parada, L. F.,
and Kaplan, D. R.
(1992)
Neuron
9,
883-896
|
| 27.
|
Baudet, C.,
Mikaels, A.,
Westphal, H.,
Johansen, J.,
Johansen, T. E.,
and Ernfors, P.
(2000)
Development
127,
4335-4344
|
| 28.
|
Salvatore, D.,
Barone, M. V.,
Salvatore, G.,
Melillo, R. M.,
Chiappetta, G.,
Mineo, A.,
Fenzi, G.,
Vecchio, G.,
Fusco, A.,
and Santoro, M.
(2000)
J. Clin. Endocrinol. Metab.
85,
3898-3907
|
| 29.
|
Hubbard, S. R.,
Wei, L.,
Ellis, L.,
and Hendrickson, W. A.
(1994)
Nature
372,
746-754
|
| 30.
|
Dickens, M.,
Tavare, J. M.,
Clack, B.,
Ellis, L.,
and Denton, R. M.
(1991)
Biochem. Biophys. Res. Commun.
174,
772-778
|
| 31.
|
Segal, R. A.,
Bhattacharyya, A.,
Rua, L. A.,
Alberta, J. A.,
Stephens, R. M.,
Kaplan, D. R.,
and Stiles, C. D.
(1996)
J. Biol. Chem.
271,
20175-20181
|
| 32.
|
Saarma, M.
(2000)
Eur. J. Biochem.
267,
6968-6971
|
| 33.
|
Minichiello, L.,
Casagranda, F.,
Tatche, R. S.,
Stucky, C. L.,
Postigo, A.,
Lewin, G. R.,
Davies, A. M.,
and Klein, R.
(1998)
Neuron
21,
335-345
|
| 34.
|
Haugh, J. M.,
Schooler, K.,
Wells, A.,
Wiley, H. S.,
and Lauffenburger, D. A.
(1999)
J. Biol. Chem.
274,
8958-8965
|
| 35.
|
Sweeney, C.,
Lai, C.,
Riese, D. J.,
Diamonti, A. J.,
Cantley, L. C.,
and Carraway, K. L.
(2000)
J. Biol. Chem.
275,
19803-19807
|
| 36.
|
Creedon, D. J.,
Tansey, M. G.,
Baloh, R. H.,
Osborne, P. A.,
Lampe, P. A.,
Fahrner, T. J.,
Heuckeroth, R. O.,
Milbrandt, J.,
and Johnson, E. M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
7018-7023
|
| 37.
|
Akerud, P.,
Alberch, J.,
Eketjall, S.,
Wagner, J.,
and Arenas, E.
(1999)
J. Neurochem.
73,
70-78
|
| 38.
|
Trupp, M.,
Scott, R.,
Whittemore, S. R.,
and Ibáñez, C. F.
(1999)
J. Biol. Chem.
274,
20885-20894
|
| 39.
|
Poteryaev, D.,
Titievsky, A.,
Sun, Y. F.,
Thomas-Crusells, J.,
Lindahl, M.,
Billaud, M.,
Arumae, U.,
and Saarma, M.
(1999)
FEBS Lett.
463,
63-66
|
| 40.
|
Worley, D. S.,
Pisano, J. M.,
Choi, E. D.,
Walus, L.,
Hession, C. A.,
Cate, R. L.,
Sanicola, M.,
and Birren, S. J.
(2000)
Development
127,
4383-4393
|
| 41.
|
Baloh, R. H.,
Tansey, M. G.,
Lampe, P. A.,
Fahrner, T. J.,
Enomoto, H.,
Simburger, K. S.,
Leitner, M. L.,
Araki, T.,
Johnson, E. M.,
and Milbrandt, J.
(1998)
Neuron
21,
1291-1302
|
| 42.
|
Moore, M. W.,
Klein, R. D.,
Farinas, I.,
Sauer, H.,
Armanini, M.,
Phillips, H.,
Reichardt, L. F.,
Ryan, A. M.,
Carvermoore, K.,
and Rosenthal, A.
(1996)
Nature
382,
76-79
|
| 43.
|
Boucher, T. J.,
Okuse, K.,
Bennett, D. L. H.,
Munson, J. B.,
Wood, J. N.,
and McMahon, S. B.
(2000)
Science
290,
124-127
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Vargiolu, D. Fusco, I. Kurelac, D. Dirnberger, R. Baumeister, I. Morra, A. Melcarne, R. Rimondini, G. Romeo, and E. Bonora
The Tyrosine Kinase Receptor RET Interacts in Vivo with Aryl Hydrocarbon Receptor-Interacting Protein to Alter Survivin Availability
J. Clin. Endocrinol. Metab.,
July 1, 2009;
94(7):
2571 - 2578.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-H. Kim, H.-B. Kim, S. Acharya, H.-M. Sohn, J. Y. Jun, I.-Y. Chang, and H. J. You
Ape1/Ref-1 Induces Glial Cell-Derived Neurotropic Factor (GDNF) Responsiveness by Upregulating GDNF Receptor {alpha}1 Expression
Mol. Cell. Biol.,
April 15, 2009;
29(8):
2264 - 2277.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Parkash, V.-M. Leppanen, H. Virtanen, J. M. Jurvansuu, M. M. Bespalov, Y. A. Sidorova, P. Runeberg-Roos, M. Saarma, and A. Goldman
The Structure of the Glial Cell Line-derived Neurotrophic Factor-Coreceptor Complex: INSIGHTS INTO RET SIGNALING AND HEPARIN BINDING
J. Biol. Chem.,
December 12, 2008;
283(50):
35164 - 35172.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. W. Gould, S. Yonemura, R. W. Oppenheim, S. Ohmori, and H. Enomoto
The Neurotrophic Effects of Glial Cell Line-Derived Neurotrophic Factor on Spinal Motoneurons Are Restricted to Fusimotor Subtypes
J. Neurosci.,
February 27, 2008;
28(9):
2131 - 2146.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. F. Yoong and H.-P. Too
Glial Cell Line-Derived Neurotrophic Factor and Neurturin Inhibit Neurite Outgrowth and Activate RhoA through GFR{alpha}2b, an Alternatively Spliced Isoform of GFR{alpha}2
J. Neurosci.,
May 23, 2007;
27(21):
5603 - 5614.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. O Ceyhan, F. Bergmann, M. Kadihasanoglu, M. Erkan, W. Park, U. Hinz, T. Giese, M. W Muller, M. W Buchler, N. A Giese, et al.
The neurotrophic factor artemin influences the extent of neural damage and growth in chronic pancreatitis
Gut,
April 1, 2007;
56(4):
534 - 544.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. P. Knowles, J. Murray-Rust, S. Kjaer, R. P. Scott, S. Hanrahan, M. Santoro, C. F. Ibanez, and N. Q. McDonald
Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain
J. Biol. Chem.,
November 3, 2006;
281(44):
33577 - 33587.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ma, J. Li, I. Chiu, Y. Wang, J. A. Sloane, J. Lu, B. Kosaras, R. L. Sidman, J. J. Volpe, and T. Vartanian
Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis
J. Cell Biol.,
October 23, 2006;
175(2):
209 - 215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
Endocr. Rev.,
August 1, 2006;
27(5):
535 - 560.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. A. Pierchala, J. Milbrandt, and E. M. Johnson Jr
Glial cell line-derived neurotrophic factor-dependent recruitment of Ret into lipid rafts enhances signaling by partitioning Ret from proteasome-dependent degradation.
J. Neurosci.,
March 8, 2006;
26(10):
2777 - 2787.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Santoro, R. M. Melillo, F. Carlomagno, G. Vecchio, and A. Fusco
Minireview: RET: Normal and Abnormal Functions
Endocrinology,
December 1, 2004;
145(12):
5448 - 5451.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Crowder, H. Enomoto, M. Yang, E. M. Johnson Jr., and J. Milbrandt
Dok-6, a Novel p62 Dok Family Member, Promotes Ret-mediated Neurite Outgrowth
J. Biol. Chem.,
October 1, 2004;
279(40):
42072 - 42081.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Kawamoto, K. Takeda, Y. Okuno, Y. Yamakawa, Y. Ito, R. Taguchi, M. Kato, H. Suzuki, M. Takahashi, and I. Nakashima
Identification of RET Autophosphorylation Sites by Mass Spectrometry
J. Biol. Chem.,
April 2, 2004;
279(14):
14213 - 14224.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Arighi, A. Popsueva, D. Degl'Innocenti, M. G. Borrello, C. Carniti, N. M. Perala, M. A. Pierotti, and H. Sariola
Biological Effects of the Dual Phenotypic Janus Mutation of ret Cosegregating with Both Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease
Mol. Endocrinol.,
April 1, 2004;
18(4):
1004 - 1017.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. A. Tsui-Pierchala, R. C. Ahrens, R. J. Crowder, J. Milbrandt, and E. M. Johnson Jr.
The Long and Short Isoforms of Ret Function as Independent Signaling Complexes
J. Biol. Chem.,
September 6, 2002;
277(37):
34618 - 34625.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|